Canadian Generic Pharmaceutical Association (CGPA)
| Specific Topics of Lobbying Communications | Intended Outcomes | Associated Subject Matters |
|---|---|---|
|
Accelerating listing of generic drugs through regulatory reform.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity, Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation
|
Health
|
|
Addressing and minimizing use of brand coupon cards.
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Addressing and minimizing use of brand coupon cards.
Commencement of negotiations to renew Agreement with pan-Canadian Pharmaceutical Alliance, including potential framework on biosimilars.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
BC's biosimilar initiative and increasing market share of biosimilars products in British Columbia.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Commencement of negotiations to renew Agreement with pan-Canadian Pharmaceutical Alliance, including potential framework on biosimilars.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Discussions of British Columbia's position on the National Pharmacare initiative in a manner congruent with the interests of generic pharmaceutical manufacturers.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Encouraging British Columbia to direct the pan Canadian Pharmaceutical Alliance to negotiate a sustainable pricing regime with the generic manufacturing sector.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Expansion of reimbursement criteria by the Government of British Columbia for biosimilar products.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Implementation of commitments made by British Columbia pursuant to its involvement with the pan-Canadian Pharmaceutical Alliance.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Improved demand forecasts and purchasing commitments from hospitals
|
Decision by the Executive Council or a member of the Executive Council to have the private sector instead of the Crown provide goods or services to the government of British Columbia or a Provincial entity, Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Maintenance of bilateral meetings between the Ministry of Health and the CGPA.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Measures to strengthen Canada's domestic pharmaceutical industry
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Promoting greater utilization of generic prescription medicines.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Proposal of a pilot project to increase utilization of generic specialty products.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Provincial government policy on opioid prescribing and dispensing and proper role of generic manufacturers.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Requesting firm notification of price changes for generic products.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Support for CGPA pricing proposals in current negotiations with pan-Canadian Pharmaceutical Alliance for renewal of agreement with pCPA.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|
|
Support for concerns relating to Canadian-specific requirement for insulin pumps for use with Biosimilar products.
|
Development, establishment, amendment or termination of any program, policy, directive or guideline of the government of British Columbia or a Provincial entity
|
Health
|